Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC

The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Florez (DUMA), Narjust, Mcdonald, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184836/
https://www.ncbi.nlm.nih.gov/pubmed/37197732
http://dx.doi.org/10.6004/jadpro.2023.14.3.12
Descripción
Sumario:The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non–small cell lung cancer.

Ejemplares similares